title: Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning.
abstract: Recognition and treatment of schizophrenia has largely focused on positive symptoms of the disorder, such as delusions, hallucinations, and disorganization. However, other important symptoms, such as depression, cognition, and social functioning, have not received comparable attention. Fifty percent of schizophrenic patients suffer from comorbid depression, which is a major risk factor for suicide in this population, while 10% to 25% suffer from comorbid obsessive-compulsive disorder. Cognitive deficits commonly observed in patients with schizophrenia include problems with concentration, attention, and memory, as well as problem-solving and verbal skills. These deficits are observed at early stages of the illness and can predict deficits in functional capabilities, such as occupational and social skills, educational attainment, and the ability to live independently. The severity of such impairments affects all patient in this population, including up to 10% of patients working full time and up to one third of those working part time. In light of the debilitating effects of depression, cognitive impairment, and other aspects of affective functioning on the quality of life of patients with schizophrenia, physicians need to partner with their patients to address these concerns and determine an appropriate treatment regimen. This can be done with simple functional-based cognitive questioning, the use of evidence-based psychosocial practices, and psychoeducation on the many pharmacotherapeutic options. It is recommended that depressive or suicidal symptoms of schizophrenia be treated with an antidepressant or mood stabilizer only if the symptoms have not subsided after treatment of the psychosis with an atypical antipsychotic. Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments.
authors.affiliation: Georgetown University School of Medicine, USA.
authors.forename: David L
authors.initials: DL
authors.lastname: Ginsberg
authors.forename: Nina R
authors.initials: NR
authors.lastname: Schooler
authors.forename: Peter F
authors.initials: PF
authors.lastname: Buckley
authors.forename: Philip D
authors.initials: PD
authors.lastname: Harvey
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Weiden
mesh_terms: D000342:Affective Symptoms / Q000523:psychology / Q000534:rehabilitation*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003072:Cognition Disorders / Q000523:psychology / Q000534:rehabilitation*; D003131:Combined Modality Therapy; D003863:Depression / Q000523:psychology / Q000534:rehabilitation*; D019317:Evidence-Based Medicine; D010353:Patient Education as Topic; D017060:Patient Satisfaction; D012559:Schizophrenia / Q000175:diagnosis / Q000534:rehabilitation*; D012565:Schizophrenic Psychology
chemical_list: D000928:Antidepressive Agents; D018692:Antimanic Agents